ArticlePloS one2025
Green-synthesized zinc oxide nanoparticles using Echinops spinosus extract: A promising anticancer agent for hepatocellular carcinoma.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustainable nanomedicine from olive leaf waste: biosynthesized ZnONPs with mechanistic validation against hepatocellular carcinoma.RSC advances · 2026Article
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The environmentally sustainable synthesis of nanoparticles has arisen as a viable alternative to traditional methods, tackling ecological and economic issues. This research investigates the green synthesis of ZnO nanoparticles utilizing an aqueous extract of Echinops Spinosus L. roots (ESRE), abundant in bioactive chemicals, as a natural reducing agent. The impacts of different quantities of precursors and reducing agents were methodically examined. The synthesized ZnO nanoparticles were characterized by zeta potential measurements (-15.2 mV), transmission electron microscopy (TEM), which indicated spherical and hexagonal morphologies with an average size of 20.47-48.22 nm, and energy-dispersive X-ray spectroscopy (EDX), confirming zinc and oxygen as the principal elements. Fourier transform infrared spectroscopy (FTIR) underscored plant-derived compounds' contribution to nanoparticle stabilization. Cytotoxicity was assessed using the MTT assay on two cancer cell lines, HepG2 (hepatocellular carcinoma) and MCF-7 (breast cancer). The green-synthesized ZnO nanoparticles had substantial anticancer efficacy, with the ZnO nanoparticles exhibiting the most pronounced anti-proliferative effect on HepG2 cells (10.4 folds) and 5.4 folds more effective in MCF-7 cells compared to ESRE, with HepG2 cells IC50 value of 19.94 ± 0.11 µg/mL while the IC50 for MCF-7 cells was 75.65 ± 0.16 µg/mL. The results indicate that ZnO-NPs produced by green technologies exhibit significant potential as anticancer agents, especially for hepatocellular carcinoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.